Credit: Unsplash / CC0 Public Domain
A national registry to record all pharmaceutical / medical device industry payments and other benefits to all clinicians, health organizations and patient support groups should be urgently established in the UK, an editorial in the Drug and Therapeutics Bulletin emphasizes.
The UK government, despite the recommendations of a key review published last July, and the support of most organizations representing medical practitioners, has found its bearings on the matter, according to dtb’s assistant editor David Phizackerley.
One of the nine recommendations of the Independent Medicines and Medical Devices Safety Review (IMMDSR) on the preventable harms caused by hormone pregnancy tests, sodium valproate, and pelvic mesh implants, focused on financial links between drug and medical device companies and clinicians, hospitals, and other organizations.
The evidence presented to the review has shown that there is a lack of transparency regarding industry payments / in-kind services and that these links may have implications not only for individual practice but also for the organizations involved in the provision of advice, guidance and support Regulation are involved, he writes.
The review requested that physician registration include a statement of financial and non-financial interests, as well as mandatory reporting of commercial payments to teaching hospitals, research institutions and individual clinicians.
Dtb also raised the issue in February last year. “This is not a new topic that we and many individuals, magazines and organizations recognize as important and believe that it should be promoted widely,” writes the author.
“However, in the UK it is still not easy to find information about the relationship (financial or otherwise) between pharmaceutical and medical device companies, as well as clinicians, healthcare providers and patient support organizations.
“In addition, it is not clear whether patients are made aware when a service is funded, supported or supported by a pharmaceutical or medical device manufacturer,” he emphasizes.
Doctors have set up the Sunshine UK website so they can record their financial and commercial interests. However, it is voluntary and does not cover any other health professional, organization, or service, he says.
Similarly, Disclosure UK, the Association of the UK Pharmaceutical Industry’s database of payments and benefits to health professionals and organizations, “is not comprehensive and has been reported in reports criticized for inadequate information on payments and beneficiaries and the ability for clinicians to opt out his, “he explains.
Several other countries, including the US, France, Portugal and Latvia, have managed to put in place mandatory reporting systems. It is time for Britain to do the same, he says.
“We believe that a national registry should be established that requires pharmaceutical and medical device manufacturers to report all payments (and other benefits) to all health professionals, health organizations and patient support organizations by law.
“Access to the registry should be made public so that details of counseling, financial interests and sponsorship agreements are easy to find. In addition, healthcare providers should be required to notify patients when they have received support from pharmaceutical and medical device companies,” he writes .
And he concludes: “Despite the [Department of Health and Social Care’s] Acknowledging that the issue of the publication of declarations of interest is being examined, it has not set a timetable or work program to ensure this.
“This is a missed opportunity to demonstrate more openness and transparency, and one that needs to be corrected quickly. The public has a right to know.”
Widespread conflicts of interest between patient advocacy organizations identified in the study
Editorial: Time for Transparency, Drug and Therapeutics Bulletin, DOI: 10.1136 / dtb.2021.000008 Provided by the British Medical Journal
Quote: Establishment of a national register to record payments from pharmaceutical companies to doctors and patient support groups (2021, April 19), accessed on April 19, 2021 from https://medicalxpress.com/news/2021-04-national-registry-capture- pharma-company .html
This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.